Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913306 | 0.71 | POLB (0.40) | LMNAMEN1KMT2APOLBNPC1 | |
| SCHEMBL2917141 | 0.65 | NPC1 (0.40) | LMNAMEN1KMT2ANPC1AKR1B1 | |
| Hydrochloric Acid SCHEMBL4834247 | 0.64 | CCR5 (0.45) | LMNAMEN1KMT2APOLBNPC1 | |
| SCHEMBL1691249 | 0.63 | L3MBTL1 (0.43) | MEN1KMT2ANPC1L3MBTL1ALDH1A1 | |
| SCHEMBL10968702 | 0.63 | ATM (0.48) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL27848979 | 0.62 | F10 (0.42) | MEN1KMT2ANPC1L3MBTL1ALDH1A1 | |
| SCHEMBL4837092 | 0.62 | CCR5 (0.54) | LMNAMEN1KMT2ANPC1AKR1B1 | |
| SCHEMBL511950 | 0.62 | POLB (0.56) | POLBL3MBTL1ALDH1A1MAPT | |
| SCHEMBL29640755 | 0.62 | POLB (0.56) | POLBL3MBTL1ALDH1A1MAPT | |
| SCHEMBL924496 | 0.62 | KMT2A (0.63) | MEN1KMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979355-B1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2010-08-18 | — | — | EP | disclosed |
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| EP-1979355-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007087448-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | PPARD, PPARG, PPARA | LMNA 2231/4885MEN1 4719/4885KMT2A 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.